138 related articles for article (PubMed ID: 12721335)
1. BM-573, a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, prevents pig myocardial infarction induced by coronary thrombosis.
Rolin S; Petein M; Tchana-Sato V; Dogne JM; Benoit P; Lambermont B; Ghuysen A; Kolh P; Masereel B
J Pharmacol Exp Ther; 2003 Jul; 306(1):59-65. PubMed ID: 12721335
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion.
Kolh P; Rolin S; Tchana-Sato V; Pétein M; Ghuysen A; Lambermont B; Hanson J; Magis D; Segers P; Masereel B; D'Orio V; Dogne JM
Prostaglandins Other Lipid Mediat; 2006 Mar; 79(1-2):53-73. PubMed ID: 16516810
[TBL] [Abstract][Full Text] [Related]
3. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist.
Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM
J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of N-tert-butyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea (BM-573), a novel thromboxane A2 receptor antagonist and thromboxane synthase inhibitor in a rat model of arterial thrombosis and its effects on bleeding time.
Dogné JM; Hanson J; de Leval X; Kolh P; Tchana-Sato V; de Leval L; Rolin S; Ghuysen A; Segers P; Lambermont B; Masereel B; Pirotte B
J Pharmacol Exp Ther; 2004 May; 309(2):498-505. PubMed ID: 14742735
[TBL] [Abstract][Full Text] [Related]
6. Characterization of an original model of myocardial infarction provoked by coronary artery thrombosis induced by ferric chloride in pig.
Dogné JM; Rolin S; Pétein M; Tchana-Sato V; Ghuysen A; Lambermont B; Hanson J; Magis D; Segers P; Pirotte B; Masereel B; Drion P; D'Orio V; Kolh P
Thromb Res; 2005; 116(5):431-42. PubMed ID: 16122556
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
Ghuysen A; Dogné JM; Chiap P; Rolin S; Masereel B; Lambermont B; Kolh P; Tchana-Sato V; Hanson J; D'Orio V
Cardiovasc Drug Rev; 2005; 23(1):1-14. PubMed ID: 15867944
[TBL] [Abstract][Full Text] [Related]
8. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
[TBL] [Abstract][Full Text] [Related]
9. In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk.
Suzuki Y; Lyons JK; Yeung AC; Ikeno F
Catheter Cardiovasc Interv; 2008 Jan; 71(1):100-7. PubMed ID: 17985383
[TBL] [Abstract][Full Text] [Related]
10. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
Guth BD; Müller TH
Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
[TBL] [Abstract][Full Text] [Related]
11. Thromboxane synthetase inhibition and thromboxane receptor blockade preserve pulmonary and circulatory function in a porcine burn sepsis model.
Iglesias G; Zeigler ST; Lentz CW; Traber DL; Herndon DN
J Am Coll Surg; 1994 Aug; 179(2):187-92. PubMed ID: 8044389
[TBL] [Abstract][Full Text] [Related]
12. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model.
Toki Y; Hieda N; Okumura K; Hashimoto H; Ito T; Ogawa K; Satake T
Arzneimittelforschung; 1988 Feb; 38(2):224-7. PubMed ID: 3370068
[TBL] [Abstract][Full Text] [Related]
13. The effect of xenon anesthesia on the size of experimental myocardial infarction.
Baumert JH; Hein M; Gerets C; Baltus T; Hecker KE; Rossaint R
Anesth Analg; 2007 Nov; 105(5):1200-6, table of contents. PubMed ID: 17959941
[TBL] [Abstract][Full Text] [Related]
14. [MR imaging of injected magnetically labeled stem cells in myocardial infarction: experiment with pigs].
Qi CM; Ma GS; Liu NF; Chen Z; Shen CX; Liu XJ; Hu YP; Su YM; Li X; Teng GJ; Ju SH; Zhang XL; Gu N
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(22):1523-6. PubMed ID: 17785100
[TBL] [Abstract][Full Text] [Related]
15. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase.
Cherdon C; Rolin S; Hanson J; Ooms A; de Leval L; Drion P; Michiels C; Pirotte B; Masereel B; Sakalihassan N; Defraigne JO; Dogné JM
Prostaglandins Other Lipid Mediat; 2011 Apr; 94(3-4):124-32. PubMed ID: 21397034
[TBL] [Abstract][Full Text] [Related]
16. Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban).
van der Hoorn JW; Jukema JW; Bekkers ME; Princen HM; Corda S; Emeis JJ; Steendijk P
Crit Care Med; 2008 Sep; 36(9):2576-82. PubMed ID: 18679128
[TBL] [Abstract][Full Text] [Related]
17. A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice.
Cyrus T; Yao Y; Ding T; Dogné JM; Praticò D
Eur J Pharmacol; 2007 Apr; 561(1-3):105-11. PubMed ID: 17306791
[TBL] [Abstract][Full Text] [Related]
18. The novel thromboxane A2 receptor antagonist KW-3635 reduces infarct size in a canine model of coronary occlusion and reperfusion.
Higo K; Sano J; Karasawa A; Kubo K
Arch Int Pharmacodyn Ther; 1993; 323():32-49. PubMed ID: 8250642
[TBL] [Abstract][Full Text] [Related]
19. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.
Dogné JM; Rolin S; de Leval X; Benoit P; Neven P; Delarge J; Kolh P; Damas J; David JL; Masereel B
Cardiovasc Drug Rev; 2001; 19(2):87-96. PubMed ID: 11484064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
